The everolimus eluting Synergy MegatronTM drug‐eluting stent platform: Early outcomes from the European Synergy MegatronTM Implanters' Registry.

MLA

De Silva, Kalpa, et al. “The Everolimus Eluting Synergy MegatronTM Drug‐eluting Stent Platform: Early Outcomes from the European Synergy MegatronTM Implanters’ Registry.” Catheterization & Cardiovascular Interventions, vol. 102, no. 7, Dec. 2023, pp. 1222–28. EBSCOhost, https://doi.org/10.1002/ccd.30902.

APA

De Silva, K., Li Kam Wa, M. E., Wells, T., Mozid, A., Ladwiniec, A., Hynes, B. G., Kotecha, A., Ratib, K., Biswas, S., Amabile, N., Deharo, P., McEntagart, M., Spratt, J. C., Digne, F., Hogg, M., Mailey, J. A., Walsh, S. J., & Kalra, S. S. (2023). The everolimus eluting Synergy MegatronTM drug‐eluting stent platform: Early outcomes from the European Synergy MegatronTM Implanters’ Registry. Catheterization & Cardiovascular Interventions, 102(7), 1222–1228. https://doi.org/10.1002/ccd.30902

Chicago

De Silva, Kalpa, Matthew E. Li Kam Wa, Tim Wells, Abdul Mozid, Andrew Ladwiniec, Brian G. Hynes, Ashish Kotecha, et al. 2023. “The Everolimus Eluting Synergy MegatronTM Drug‐eluting Stent Platform: Early Outcomes from the European Synergy MegatronTM Implanters’ Registry.” Catheterization & Cardiovascular Interventions 102 (7): 1222–28. doi:10.1002/ccd.30902.